跳至主要内容
临床试验/JPRN-jRCT1011180032
JPRN-jRCT1011180032进行中(未招募)2 期

eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trial - HOPS-R02

Hirano Satoshi0 个研究点目标入组 50 人开始时间: 2019年3月27日最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 79age old(—)
性别
All

入选标准

  • 1.Resectable pancreatic cancer (JPS7th)
  • 2.Pathological or cytologically proven invasive ductal adenocarcinoma or adenosquamous carcinoma
  • 3.No distant metastasis
  • 4.Age over 20 or under 80
  • 5.ECOG performance status 0-1
  • 6.No history of chemo therapy within 3 years.
  • 7.No history of pancreatic cancer therapy
  • 8.No problems for oral intake
  • 9.Neither peripheral sensory neuropathy nor peripheral motor neuropathy
  • 10.In the case of obstructive jaundice, appropriate bileduct drainage is performed
  • 11.No findings of gastrointestinal infiltration protruding into the lumen and or gastrointestinal bleeding
  • 12.The latest inspection value within 2 weeks before registration satisfies all of the following.
  • 1) White blood cell count more than 3,000 / mm 3
  • 2) Hemoglobin more than 9.0 g / dL (no transfuse within 7 days before registration)
  • 3) Platelet count more than 10 x 10 4 / mm 3
  • 4) Albumin more than 3.0 g / dL
  • 5) Total bilirubin less than 2.0 mg / dL (3.0 mg / dL or less in case of bileduct drainarge)
  • 6) AST less than 100 U / L (150 IU / L or less in case of bileduct drainarge)
  • 7) ALT less than 100 U / L (150 IU / L or less in case of bileduct drainarge)
  • 8) Serum creatinine less than 1.2 mg / dL
  • 9) Creatinine clearance 50 ml / min or more
  • 13.Written informed consent

排除标准

  • 1.GEM, nab-PTX or fluorinated pyrimidine anticancer drugs have been treated.
  • 2.Severe diarrhea with uncontrolled bowel movement
  • 3.Phenytoin, warfarin potassium, flucytosine are used.
  • 4.History of sever allergic reaction with nab-paclitaxel, paclitaxel or albumin
  • 5.Drug allergy to iodine contrast medium and impossible to perform contrast CT imaging. However, do not exclude the case of contrast-enhanced CT imaging with steroid prophylaxis.
  • 6.Pulmonary fibrosis or interstitial pneumonia
  • 7.Patients with medium or more pleural effusion or ascites
  • 8.Active infection (Clinically stable HBV and chronic viral hepatitis by HCV are excluded).
  • 9.Uncontrolled diabetes
  • 10.Active double cancer (Synchronous double cancer and metachronous double cancer with disease-free period within 3 years). However, lesions such as carcinoma in situ that are cured by topical therapy are not included in active double cancers.
  • 11.Active digestive ulcer
  • 12.Serious complications (heart failure, renal failure, liver failure, intestinal palsy, etc).
  • 13.Myocardial infarction within six months
  • 14.Continuous systemic administration of steroids
  • 15.Sever mental disorder
  • 16.Women who are pregnant / lactating or pregnant or willing, or wish to baby.
  • 17.A man who wishes to become a partner's pregnant.
  • 18.Inappropriate physical condition as diagnosed by the attending physician

研究者

发起方
Hirano Satoshi

相似试验

已完成
不适用
eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trialResectable pancreatic cancer
JPRN-UMIN000031822Hokkaido Pancreatic Cancer Study Group (HOPS)50
尚未招募
2 期
eoadjuvant Gemcitabine+nab-Paclitaxel for resectable and borderline resectable pancreatic cancer-feasibility study for the elderlyResectable and Borderline resectable pancreatic cancer
JPRN-UMIN000048555Hyogo Prefectural Awaji Medical Center50
进行中(未招募)
1 期
Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Gemcitabine or Continuing Application of nab-Paclitaxel/Gemcitabine: A Randomized Phase II Studymetastatic pancreatic cancerMedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864
EUCTR2014-004086-24-DEAIO-Studien-gGmbH325
已完成
不适用
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for borderline resectable pancreatic cancer: Phase I studypancreatic cancer
JPRN-UMIN000012456Department of Gastroenterological Surgery, Osaka Medical Center for Cancer &amp; Cardiovascular Diseases42
招募中
2 期
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable pancreatic cancer: Phase II studypancreatic cancer
JPRN-UMIN000018803Department of Gastroenterological Surgery, Osaka Medical Center for Cancer &amp; Cardiovascular Diseases50